Cingulate Inc. (CINGW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cingulate Inc. (CINGW) trades at $0.0118. Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and neurobiological disorders, primarily ADHD and anxiety. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CINGW: CINGW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CINGW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on CINGW.
How is this calculated? →Cingulate Inc. (CINGW) Healthcare & Pipeline Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, particularly ADHD, with lead candidates CTx-1301 and CTx-1302. The company aims to address unmet needs in neurobiological disorders, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for CINGW?
Cingulate Inc. presents a high-risk, high-reward investment opportunity given its clinical-stage status and focus on CNS disorders. The success of its lead product candidates, CTx-1301 and CTx-1302, in clinical trials is crucial for future growth. Positive clinical data could significantly increase the company's valuation. The company's ability to secure partnerships and funding will be essential for advancing its pipeline. The current market capitalization of $0.00B reflects the speculative nature of the investment, with a P/E ratio of -2.14, indicating a lack of current profitability. Investors should closely monitor clinical trial results and regulatory developments.
Based on FMP financials and quantitative analysis
CINGW Key Highlights
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on central nervous system disorders.
- Lead product candidates CTx-1301 and CTx-1302 target the treatment of attention deficit/hyperactivity disorder (ADHD).
- Developing CTx-2103 for the treatment of anxiety disorders, expanding its therapeutic pipeline.
- The company was founded in 2012 and is headquartered in Kansas City, Kansas, with an additional location in Morristown, New Jersey.
- Market capitalization of $0.00B reflects its early stage and speculative nature.
Who Are CINGW's Competitors?
CINGW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APM Aptorum Group Limited | $8.26 | -14.84% | $5.24M | 43 |
| APVO Aptevo Therapeutics Inc. | $2.84 | +4.03% | $6.21M | — |
| BOLT Bolt Biotherapeutics, Inc. | $3.20 | -1.84% | $6.15M | — |
| COCP Cocrystal Pharma, Inc. | $1.17 | +2.18% | $16.1M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CINGW's Key Strengths?
Focus on unmet needs in CNS disorders
- Proprietary drug formulations
- Experienced management team
- Pipeline of product candidates in clinical development
What Are CINGW's Weaknesses?
Clinical-stage company with no approved products
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High risk of regulatory setbacks
What Could Drive CINGW Stock Higher?
Clinical trial results for CTx-1301 and CTx-1302 in ADHD patients.
- FDA regulatory milestones for CTx-1301 and CTx-1302.
- Clinical trial initiation for CTx-2103 in anxiety disorder patients.
- Strategic partnerships and collaborations to fund clinical development.
- Patent filings and intellectual property protection for novel formulations.
What Are the Key Risks for CINGW?
Financial-distress signal — its Altman Z-Score of -6.14 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive clinical trial results for its product candidates.
- Regulatory setbacks and delays in FDA approval process.
- Competition from established pharmaceutical companies with approved ADHD and anxiety treatments.
- Dependence on securing additional funding to support clinical development.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for CINGW?
- Advancement of CTx-1301 and CTx-1302 through clinical trials: Successful completion of Phase 3 trials and subsequent FDA approval for CTx-1301 and CTx-1302 would represent a significant growth catalyst for Cingulate. Positive clinical data could lead to partnerships with larger pharmaceutical companies, providing additional funding and resources. Timeline: Ongoing clinical trials with potential FDA submission within the next 2-3 years.
- Development and commercialization of CTx-2103 for anxiety disorders: Expanding its pipeline to include treatments for anxiety disorders provides Cingulate with another significant growth opportunity. The anxiety disorders market is also substantial, with a large patient population seeking effective therapies. Successful development and commercialization of CTx-2103 could diversify Cingulate's revenue streams and reduce its reliance on ADHD treatments. Timeline: Pre-clinical and early clinical development with potential market entry in 3-5 years.
- Strategic partnerships and collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Cingulate with access to additional funding, expertise, and resources. These partnerships could accelerate the development and commercialization of its product candidates and expand its market reach. Collaborations could also lead to the discovery of new therapeutic targets and the development of innovative treatments for CNS disorders. Timeline: Ongoing efforts to establish partnerships with potential agreements within the next 1-2 years.
- Expansion into new therapeutic areas within CNS disorders: Cingulate could leverage its expertise in CNS disorders to expand its pipeline into new therapeutic areas, such as depression, bipolar disorder, or Alzheimer's disease. These markets represent significant growth opportunities, with a large unmet need for effective treatments. Expanding its pipeline would diversify Cingulate's revenue streams and reduce its reliance on ADHD and anxiety treatments. Timeline: Long-term strategy with potential pipeline expansion in 3-5 years.
- Geographic expansion into international markets: Following successful commercialization in the United States, Cingulate could expand its market reach into international markets, such as Europe and Asia. These markets represent significant growth opportunities, with a large patient population seeking effective treatments for CNS disorders. Geographic expansion would require regulatory approvals and partnerships with local distributors. Timeline: Long-term strategy with potential international expansion in 5+ years.
What Are CINGW's Competitive Advantages?
- Proprietary drug formulations (CTx-1301, CTx-1302, CTx-2103)
- Patent protection on its product candidates
- Clinical data supporting the efficacy and safety of its products
- Expertise in developing treatments for CNS disorders
What Does CINGW Do?
Founded in 2012, Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) and neurobiological disorders. The company's primary focus is on addressing the unmet needs in the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety disorders. Cingulate's lead product candidates include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed for the treatment of ADHD. These product candidates are formulated to provide a differentiated approach to managing ADHD symptoms. Additionally, Cingulate is developing CTx-2103 for the treatment of anxiety disorders, further expanding its pipeline of CNS-focused therapeutics. Headquartered in Kansas City, Kansas, with an additional location in Morristown, New Jersey, Cingulate is working to advance its clinical programs and bring novel therapies to patients. The company operates with a team of 13 employees under the leadership of CEO Shane J. Schaffer.
What Products and Services Does CINGW Offer?
- Develops product candidates for central nervous system (CNS) disorders.
- Focuses on treatments for attention deficit/hyperactivity disorder (ADHD).
- Develops treatments for anxiety disorders.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approval from the FDA for its product candidates.
- Aims to commercialize its approved products and make them available to patients.
How Does CINGW Make Money?
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval for commercialization.
- Out-licenses or commercializes approved products directly.
What Industry Does CINGW Operate In?
The biotechnology industry is characterized by high risk and high reward, with companies like Cingulate focusing on developing novel therapies for unmet medical needs. The ADHD and anxiety disorders market is substantial, with a growing prevalence and demand for effective treatments. Competition includes established pharmaceutical companies and other emerging biotechs. Cingulate's success depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy. The industry is driven by innovation, with companies constantly seeking to develop improved treatments and address unmet needs.
Who Are CINGW's Key Customers?
- Patients with ADHD
- Patients with anxiety disorders
- Healthcare providers who prescribe medications for CNS disorders
- Pharmacies that dispense medications
Company Profile
Cingulate Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kansas City, US. The company is led by CEO Shane J. Schaffer. CINGW has traded publicly since 2021.
Financial Health
Cingulate Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.14 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Cingulate Inc. revenue of about $2.9M for fiscal 2026, with EPS near $-2.42. The estimate reflects 5 contributing analysts.
CINGW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a belief in upcoming positive developments.
- Community sentiment has shifted positively, with discussions highlighting the potential of Cingulate's product pipeline.
- Analysts are noting increased interest in the ADHD treatment market, which aligns with Cingulate's focus area, attracting attention from investors.
- Recent partnerships and collaborations have been viewed favorably, suggesting strategic growth opportunities and enhanced market positioning.
Bear Case
- Concerns remain around the competitive landscape, particularly with established players in the ADHD space, which could limit market share.
- Social sentiment has shown volatility, with some community members expressing skepticism about the company's ability to deliver on its promises.
- Recent financial disclosures raised questions about cash flow sustainability, leading to worries about operational viability in the near term.
- Market perception has been cautious, with some investors wary of the company's ability to execute its growth strategy effectively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CINGW Latest News
No recent news available for CINGW.
CINGW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CINGW.
Price Targets
Wall Street price target analysis for CINGW.
CINGW MoonshotScore
What does this score mean?
The MoonshotScore rates CINGW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Shane J. Schaffer
CEO
Shane J. Schaffer serves as the CEO of Cingulate Inc., leading a team of 13 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on CNS disorders. He has held leadership positions in various companies, overseeing drug development, clinical trials, and commercialization efforts. Schaffer's expertise spans across multiple therapeutic areas, including ADHD and anxiety disorders. His educational background includes advanced degrees in science and business, providing him with a strong foundation for leading a clinical-stage biopharmaceutical company.
Track Record: Under Shane J. Schaffer's leadership, Cingulate Inc. has advanced its lead product candidates, CTx-1301 and CTx-1302, through clinical trials. He has overseen the development of CTx-2103 for anxiety disorders, expanding the company's pipeline. Schaffer has focused on securing funding and partnerships to support the company's growth. His strategic decisions have positioned Cingulate as a key player in the development of novel treatments for CNS disorders.
Common Questions About CINGW (Healthcare)
What does Cingulate Inc. do?
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders, particularly ADHD and anxiety disorders. Its lead product candidates, CTx-1301 and CTx-1302, are designed to provide improved symptom control for ADHD patients. The company is also developing CTx-2103 for the treatment of anxiety disorders.
What are the main risks for CINGW?
As a clinical-stage biopharmaceutical company, Cingulate Inc. faces significant risks inherent in the drug development process. These include the risk of failure to achieve positive clinical trial results, regulatory setbacks and delays in FDA approval, competition from established pharmaceutical companies, and the need to secure additional funding to support clinical development.
What are the key factors to evaluate for CINGW?
Evaluate CINGW on fundamentals, analyst consensus, and risk factors. Cingulate Inc. presents a high-risk, high-reward investment opportunity given its clinical-stage status and focus on CNS disorders. Not financial advice.
How frequently does CINGW data refresh on this page?
CINGW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CINGW's recent stock price performance?
Cingulate Inc. (CINGW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet needs in CNS disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CINGW overvalued or undervalued right now?
Cingulate Inc. (CINGW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CINGW before investing?
Before investing in Cingulate Inc. (CINGW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CINGW to a portfolio?
Key strength of Cingulate Inc. (CINGW): Focus on unmet needs in CNS disorders. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- AI analysis is pending and may provide additional insights.